NCT01483599View on ClinicalTrials.gov

A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis

PHASE2CompletedINTERVENTIONAL

Enrollment

293

Participants

Timeline

Start Date

November 10, 2011

Primary Completion Date

November 27, 2012

Study Completion Date

August 5, 2013

Conditions

Psoriasis

Interventions

DRUG

CNTO 1959 (5 mg)

Subcutaneous (SC) injections

DRUG

CNTO 1959 (15 mg)

SC injections

DRUG

CNTO 1959 (50 mg)

SC injections

DRUG

CNTO 1959 (100 mg)

SC injections

DRUG

CNTO 1959 (200 mg)

SC injections

DRUG

Adalimumab

SC injections

DRUG

Placebo

SC injections

Trial Locations (40)

Unknown

Birmingham

Bakersfield

Los Angeles

Santa Monica

Ocala

Alpharetta

Arlington Heights

Skokie

Indianapolis

Louisville

Andover

Boston

St Louis

Albuquerque

New York

Portland

Pittsburgh

Houston

Brussels

Ghent

Liège

Edmonton

Vancouver

Moncton

Halifax

Hamilton

London

Oakville

Toronto

Waterloo

Montreal

Québec

Hamburg

Mahlow

Münster

Schwerin

Gdansk

Gmina Końskie

Lodz

Wroclaw

All Listed Sponsors

lead

Janssen Inc.

INDUSTRY

NCT01483599 - A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis | Biotech Hunter | Biotech Hunter